| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2010 , Vol 52 , Num 4
DISSOLUTION AND HISTOLOGICAL STUDIES ON ORNIDAZOLE VAGINAL FORMULATIONS
Department of Pharmaceutical Technology, Faculty of Pharmacy, Ege University, 35100, Bornova, İzmir, Turkey.
Viewed :
20336
-
Downloaded :
27
In this study our objective was to develop suitable vaginal formulations of ornidazole, to evaluate the physicochemical properties, to investigate the irritation potential of the formulations to the rat vaginal tissue and compare these formulations with commercially available vaginal formulation. Vaginal and effervescent vaginal tablets of ornidazole were prepared by wet granulation technique. Vaginal and effervescent vaginal suppositories were prepared by fusion method. The drug amount of the formulations was determined by a validated method using an HPLC with two different media (phosphate buffer and artificial vaginal fluid solutions). In vitro dissolution test, kinetical analysis of data and histopathological studies of the formulations were carried out. According to the dissolution studies, vaginal effervescent suppository formulation shows the fastest release with a similarity to commercially available vaginal tablet. The release mechanism was described and found to be non-Fickian for all formulations. Dissolution data were evaluated statistically. No histological damage was found for all formulations.
Keywords :
ORNIDAZOLE, VULVO-VAGINAL CANDIDIASIS, VAGINAL SUPPOSITORY, VAGINAL TABLETS, EFFERVESCENT VAGINAL FORMULATIONS